2 results
Approved WMORecruiting
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
Approved WMOPending
The primary objective of this study is to evaluate the efficacy and safety of naltrexone in the treatment of itch in patients with burn wounds. The nature of the association(s) of the - reduction of the - intensity of itch with sleep and anxiety in…